Published in Am J Pathol on August 04, 2012
Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle (2014) 1.16
DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle. Hum Mol Genet (2014) 1.06
miR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors. Orphanet J Rare Dis (2013) 0.91
A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. Elife (2015) 0.89
DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells. PLoS One (2013) 0.88
DNA-binding sequence specificity of DUX4. Skelet Muscle (2016) 0.83
Direct interplay between two candidate genes in FSHD muscular dystrophy. Hum Mol Genet (2014) 0.80
DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy. Skelet Muscle (2014) 0.78
Homologous Transcription Factors DUX4 and DUX4c Associate with Cytoplasmic Proteins during Muscle Differentiation. PLoS One (2016) 0.77
Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Mol Ther (2016) 0.76
Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4. Epigenetics (2015) 0.76
Altered expression of cyclin A 1 in muscle of patients with facioscapulohumeral muscle dystrophy (FSHD-1). PLoS One (2013) 0.76
Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes (Basel) (2017) 0.75
Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines. Skelet Muscle (2016) 0.75
PARP1 Differentially Interacts with Promoter region of DUX4 Gene in FSHD Myoblasts. J Genet Syndr Gene Ther (2016) 0.75
Mouse Dux is myotoxic and shares partial functional homology with its human paralog DUX4. Hum Mol Genet (2016) 0.75
Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. Elife (2016) 0.75
The RNA Surveillance Factor UPF1 Represses Myogenesis via Its E3 Ubiquitin Ligase Activity. Mol Cell (2017) 0.75
Control of stochasticity in eukaryotic gene expression. Science (2004) 12.85
Stochastic mRNA synthesis in mammalian cells. PLoS Biol (2006) 12.58
Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet (1992) 5.12
A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87
Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet (2003) 3.60
DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci U S A (2007) 3.32
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet (2010) 2.95
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet (2009) 2.90
The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord (2007) 2.85
An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J (2008) 2.74
Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet (2007) 2.54
Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet (2003) 2.50
Zscan4 regulates telomere elongation and genomic stability in ES cells. Nature (2010) 2.46
Single-cell observations reveal intermediate transcriptional silencing states. Mol Cell (2006) 2.43
Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature (2005) 2.42
Facioscapulohumeral muscular dystrophy. Muscle Nerve (2006) 2.40
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy. Am J Hum Genet (2007) 2.06
Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology (2010) 2.01
Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell (2007) 1.98
Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol (1999) 1.95
DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol (2010) 1.89
A distinct cyclin A is expressed in germ cells in the mouse. Development (1996) 1.84
Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med (2011) 1.80
The FSHD-associated repeat, D4Z4, is a member of a dispersed family of homeobox-containing repeats, subsets of which are clustered on the short arms of the acrocentric chromosomes. Genomics (1995) 1.77
Evidence for subtelomeric exchange of 3.3 kb tandemly repeated units between chromosomes 4q35 and 10q26: implications for genetic counselling and etiology of FSHD1. Hum Mol Genet (1996) 1.71
Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol (1996) 1.60
FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. J Med Genet (2004) 1.50
Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res (2008) 1.45
The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One (2011) 1.45
Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res (1997) 1.44
Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J Cell Mol Med (2008) 1.42
De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. Am J Hum Genet (2000) 1.37
Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol (2010) 1.34
Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle (2011) 1.34
Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet (2009) 1.33
Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol Cell (2008) 1.30
Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS One (2009) 1.25
The expansion of the PRAME gene family in Eutheria. PLoS One (2011) 1.21
Analysis of allele-specific RNA transcription in FSHD by RNA-DNA FISH in single myonuclei. Eur J Hum Genet (2009) 1.20
D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology (2003) 1.20
Identification of a genomic reservoir for new TRIM genes in primate genomes. PLoS Genet (2011) 1.20
Atypical structure and phylogenomic evolution of the new eutherian oocyte- and embryo-expressed KHDC1/DPPA5/ECAT1/OOEP gene family. Genomics (2007) 1.16
A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur J Hum Genet (2011) 1.14
Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy. Am J Hum Genet (2004) 1.13
In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. Mol Ther (2009) 1.13
Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population. Skelet Muscle (2011) 1.05
MBD3L1 and MBD3L2, two new proteins homologous to the methyl-CpG-binding proteins MBD2 and MBD3: characterization of MBD3L1 as a testis-specific transcriptional repressor. Genomics (2002) 1.04
Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled? Hum Genet (2011) 1.04
Immunodetection of human double homeobox 4. Hybridoma (Larchmt) (2011) 1.00
Expression profiling of FSHD-1 and FSHD-2 cells during myogenic differentiation evidences common and distinctive gene dysregulation patterns. PLoS One (2011) 0.99
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther (2011) 0.97
Abnormal expression of mu-crystallin in facioscapulohumeral muscular dystrophy. Exp Neurol (2007) 0.96
Somatic mosaicism in FSHD often goes undetected. Ann Neurol (2004) 0.94
Evolutionary forces shape the human RFPL1,2,3 genes toward a role in neocortex development. Am J Hum Genet (2008) 0.93
Phenotypic-genotypic correlation will assist genetic counseling in 4q35-facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl (1995) 0.92
Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression. J Med Genet (1998) 0.90
Haploid male germ cell- and oocyte-specific Mbd3l1 and Mbd3l2 genes are dispensable for early development, fertility, and zygotic DNA demethylation in the mouse. Dev Dyn (2008) 0.90
Extreme variability of expression in monozygotic twins with FSH muscular dystrophy. Neurology (1993) 0.88
Trim43a, Trim43b, and Trim43c: Novel mouse genes expressed specifically in mouse preimplantation embryos. Gene Expr Patterns (2009) 0.86
Monozygotic twins with facioscapulohumeral dystrophy (FSHD): implications for genotype/phenotype correlation. FSH-DY Group. Muscle Nerve Suppl (1995) 0.83
Equal proportions of affected cells in muscle and blood of a mosaic carrier of facioscapulohumeral muscular dystrophy. Hum Genet (2005) 0.78
A unifying genetic model for facioscapulohumeral muscular dystrophy. Science (2010) 4.87
MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol (2005) 4.57
Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming. Dev Cell (2010) 4.50
Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol Cell (2005) 4.07
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet (2003) 3.60
Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Mol Cell (2002) 3.29
Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential. Mol Cell (2004) 3.15
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol (2005) 3.07
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet (2010) 2.95
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet (2009) 2.90
MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol (2006) 2.85
Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat (2009) 2.84
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet (2012) 2.82
Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther (2007) 2.76
Essential role for Dicer during skeletal muscle development. Dev Biol (2007) 2.76
Loss of cell polarity causes severe brain dysplasia in Lgl1 knockout mice. Genes Dev (2004) 2.55
MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol (2005) 2.55
RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet (2009) 2.51
The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain (2005) 2.51
Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet (2003) 2.50
Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest (2002) 2.48
Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One (2007) 2.47
Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. J Cell Biol (2007) 2.44
Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet (2002) 2.42
Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters. EMBO J (2006) 2.38
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet (2007) 2.25
Permanent loss of cervical spinal cord function associated with the posterior approach. Anesth Analg (2006) 2.22
An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord (2007) 2.17
Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet (2002) 2.17
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
A MyoD-generated feed-forward circuit temporally patterns gene expression during skeletal muscle differentiation. Genes Dev (2004) 2.16
Regulation of thalamocortical patterning and synaptic maturation by NeuroD2. Neuron (2006) 2.15
p38 MAPK signaling regulates recruitment of Ash2L-containing methyltransferase complexes to specific genes during differentiation. Nat Struct Mol Biol (2007) 2.03
Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle. J Clin Invest (2004) 2.00
Widespread and nonrandom distribution of DNA palindromes in cancer cells provides a structural platform for subsequent gene amplification. Nat Genet (2005) 1.99
Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell (2007) 1.98
Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet (2011) 1.97
Differential genomic targeting of the transcription factor TAL1 in alternate haematopoietic lineages. EMBO J (2010) 1.82
Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med (2011) 1.80
The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell (2006) 1.78
Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation (2005) 1.77
Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med (2003) 1.76
Genomic analysis of human chromosome 10q and 4q telomeres suggests a common origin. Genomics (2002) 1.75
Regenerative potential of human skeletal muscle during aging. Aging Cell (2002) 1.73
CTCF cis-regulates trinucleotide repeat instability in an epigenetic manner: a novel basis for mutational hot spot determination. PLoS Genet (2008) 1.72
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther (2007) 1.70
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
Mineral trioxide aggregate or calcium hydroxide direct pulp capping: an analysis of the clinical treatment outcome. J Endod (2010) 1.67
Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) (2011) 1.63
Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther (2013) 1.63
Skeletal muscle ultrasound: correlation between fibrous tissue and echo intensity. Ultrasound Med Biol (2008) 1.59
Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord (2003) 1.56
Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci U S A (2009) 1.55
Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol (2005) 1.53
Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta (2006) 1.52
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Worldwide population analysis of the 4q and 10q subtelomeres identifies only four discrete interchromosomal sequence transfers in human evolution. Am J Hum Genet (2010) 1.48
Genetic and epigenetic determinants of neurogenesis and myogenesis. Dev Cell (2012) 1.47
Pbx homeodomain proteins direct Myod activity to promote fast-muscle differentiation. Development (2007) 1.47
Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol (2005) 1.46
Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res (2008) 1.45
AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J (2006) 1.44
Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther (2011) 1.42
171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2010) 1.40
Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores. Am J Hum Genet (2010) 1.38
Intrastrand annealing leads to the formation of a large DNA palindrome and determines the boundaries of genomic amplification in human cancer. Mol Cell Biol (2007) 1.36
In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia. Eur J Hum Genet (2008) 1.34
Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet (2002) 1.33
Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur J Hum Genet (2009) 1.33
Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32
Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31
Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol (2011) 1.31
Replicative aging down-regulates the myogenic regulatory factors in human myoblasts. Biol Cell (2008) 1.30
Short inverted repeats initiate gene amplification through the formation of a large DNA palindrome in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.30
Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. Clin Chem (2006) 1.29
Clinical applications of high-density surface EMG: a systematic review. J Electromyogr Kinesiol (2006) 1.29
Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Mol Cancer Res (2003) 1.28